171 related articles for article (PubMed ID: 34348844)
1. Insurance reimbursements for recombinant zoster vaccine in the private sector.
Leidner AJ; Tang Z; Guo A; Anderson TC; Tsai Y
Vaccine; 2021 Aug; 39(36):5091-5094. PubMed ID: 34348844
[TBL] [Abstract][Full Text] [Related]
2. Insurance Reimbursements for Routinely Recommended Adult Vaccines in the Private Sector.
Tsai Y; Zhou F; Lindley MC
Am J Prev Med; 2019 Aug; 57(2):180-190. PubMed ID: 31248743
[TBL] [Abstract][Full Text] [Related]
3. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
Parikh R; Widenmaier R; Lecrenier N
Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
[TBL] [Abstract][Full Text] [Related]
4. Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.
Fix J; Vielot NA; Lund JL; Weber DJ; Smith JS; Hudgens MG; Becker-Dreps S
Vaccine; 2023 Jan; 41(1):49-60. PubMed ID: 36396511
[TBL] [Abstract][Full Text] [Related]
5. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
Anderson TC; Masters NB; Guo A; Shepersky L; Leidner AJ; Lee GM; Kotton CN; Dooling KL
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(3):80-84. PubMed ID: 35051134
[TBL] [Abstract][Full Text] [Related]
6. Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults.
Janusz CB; Anderson TC; Leidner AJ; Lee GM; Dooling K; Prosser LA
Hum Vaccin Immunother; 2022 Nov; 18(5):2060668. PubMed ID: 35476029
[TBL] [Abstract][Full Text] [Related]
7. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
[TBL] [Abstract][Full Text] [Related]
8. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.
Dooling KL; Guo A; Patel M; Lee GM; Moore K; Belongia EA; Harpaz R
MMWR Morb Mortal Wkly Rep; 2018 Jan; 67(3):103-108. PubMed ID: 29370152
[TBL] [Abstract][Full Text] [Related]
9. Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data.
Lewis CY; Mishra K; Sun Y; Sechrist SJ; Arnold BF; Acharya NR
Vaccine; 2023 May; 41(23):3493-3496. PubMed ID: 37150621
[TBL] [Abstract][Full Text] [Related]
10. Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States.
Leung J; Gray EB; Anderson TC; Sharkey SM; Dooling K
Vaccine; 2022 Nov; 40(50):7187-7190. PubMed ID: 36347721
[TBL] [Abstract][Full Text] [Related]
11. Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune-Mediated Inflammatory Diseases in the US.
Leung J; Anderson TC; Dooling K; Xie F; Curtis JR
Arthritis Rheumatol; 2022 Nov; 74(11):1833-1841. PubMed ID: 35666070
[TBL] [Abstract][Full Text] [Related]
12. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
[TBL] [Abstract][Full Text] [Related]
13. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years.
Leidner AJ; Anderson TC; Hong K; Ortega-Sanchez IR; Guo A; Pike J; Prosser LA; Dooling KL
Value Health; 2023 Feb; 26(2):204-215. PubMed ID: 36243666
[TBL] [Abstract][Full Text] [Related]
15. Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients.
George S; Regan J; Awan A; O'Connor M; Foster A; Raymond K; Gorfinkel I; McNeil SA
Hum Vaccin Immunother; 2024 Dec; 20(1):2317595. PubMed ID: 38502342
[TBL] [Abstract][Full Text] [Related]
16. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
Lu A; Sun Y; Porco TC; Arnold BF; Acharya NR
Ophthalmology; 2021 Dec; 128(12):1699-1707. PubMed ID: 33892049
[TBL] [Abstract][Full Text] [Related]
18. Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).
Hurley LP; Allison MA; Dooling KL; O'Leary ST; Crane LA; Brtnikova M; Beaty BL; Allen JA; Guo A; Lindley MC; Kempe A
Vaccine; 2018 Nov; 36(48):7408-7414. PubMed ID: 30420121
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live.
Curran D; Patterson BJ; Van Oorschot D; Buck PO; Carrico J; Hicks KA; Lee B; Yawn BP
Hum Vaccin Immunother; 2019; 15(4):765-771. PubMed ID: 30625011
[TBL] [Abstract][Full Text] [Related]
20. Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019.
Patterson BJ; Chen CC; McGuiness CB; Glasser LI; Sun K; Buck PO
Hum Vaccin Immunother; 2021 Aug; 17(8):2482-2487. PubMed ID: 33849373
[No Abstract] [Full Text] [Related]
[Next] [New Search]
